Claim OwnershipOncology Brothers: Practice-Changing Cancer Discussions
Subscribed: 12Played: 149
Subscribe
© Oncology Brothers
Description
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
80 Episodes
Reverse
Welcome to another insightful episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain delve into the world of locally advanced rectal cancer, focusing on the latest treatment strategies and advancements in the field.
Joined by esteemed guests Dr. Deborah Schrag, a medical oncologist from Memorial Sloan Kettering Cancer Center, and Dr. Krishan Jethwa, a radiation oncologist from the Mayo Clinic, the discussion centers around the groundbreaking Prospect study. This study challenges the traditional approach to rectal cancer treatment, emphasizing the importance of balancing therapeutic efficacy with minimizing chronic side effects.
The conversation covers a range of topics, from the utilization of different chemotherapy regimens to the evolving paradigm of radiation therapy. Dr. Schrag and Dr. Jethwa provide valuable insights into determining the optimal treatment course for patients with locally advanced rectal cancer, including the selective omission of surgery and the significance of MSI high status in treatment decisions.
Tune in to learn about the latest advancements in rectal cancer treatment, the implications of the Prospect study, and the importance of personalized, multidisciplinary approaches in oncology care. Don't miss out on this informative discussion that sheds light on the complexities of managing rectal cancer and the evolving treatment landscape.
Stay informed and up-to-date with the Oncology Brothers podcast as they continue to explore the dynamic world of oncology treatment. Subscribe now and join the conversation!
Guests:
Dr. Deborah Schrag, Medical Oncologist, Memorial Sloan Kettering Cancer Center
Dr. Krishan Jethwa, Radiation Oncologist, Mayo Clinic
Join Rahul and Rohit Gosain, the Oncology Brothers, in this insightful podcast episode where they discuss the latest advancements in hematology and oncology. In this episode, they are joined by Dr. Mazyar Shadman from Fred Hutch Cancer Center to delve into the Sequoia and Alpine trials that led to the approval of Zanubrutinib in CLL.
Key Points Discussed:
• The Sequoia trial focused on Zanubrutinib in first-line CLL treatment, showcasing its superiority over traditional chemotherapy.
• The Alpine study compared Zanubrutinib to Ibrutinib in relapsed/refractory settings, demonstrating Zanubrutinib's efficacy and safety profile.
• Acalabrutinib and Zanubrutinib were indirectly compared in a post-analysis, shedding light on their differences.
• Dr. Shadman provides insights on managing common side effects of Zanubrutinib, highlighting its improved tolerability.
Tune in to this episode for a comprehensive discussion on Zanubrutinib in CLL, including trial outcomes, comparisons, and practical considerations for patient care. Stay informed with the Oncology Brothers as they navigate the evolving landscape of oncology treatments
Join the Oncology Brothers, Rahul and Rohit Gosain, in this informative podcast episode as they discuss the complexities of myelofibrosis, a challenging blood cancer. They are joined by expert Dr. Naveen Pemmaraju from MD Anderson Cancer Center, who provides valuable insights into diagnosing and managing myelofibrosis.
In this episode, they discuss the importance of a thorough diagnostic workup, including bone marrow biopsy, laboratory values, and clinical history. Dr. Pemmaraju highlights the significance of risk stratification using various scoring systems and the role of molecular analysis in determining prognosis.
The conversation also covers the current treatment landscape for myelofibrosis, focusing on JAK inhibitors such as ruxolitinib, fadratinib, pacritinib, and momelotinib. The hosts and guest expert explore the unique side effects of these medications and strategies for managing them effectively.
Listeners will gain valuable insights into supportive care options for anemia, thrombocytopenia, and leukopenia, including the use of erythropoietin-stimulating agents and other therapeutic interventions. The episode emphasizes the importance of considering allogeneic stem cell transplant as a potential curative option for high-risk patients.
Don't miss this comprehensive discussion on myelofibrosis, packed with practical information and expert advice. Tune in to the Oncology Brothers podcast to stay informed about the latest developments in hematology and oncology.
In this podcast episode from the Oncology Brothers delve into the needs of different patient populations in colorectal cancer. Joined by Dr. Tanios Bekaii-Saab, a medical oncologist, and Ms. Deneen Richmond, a patient advocate, nurse, and the President of the Doctors Community Medical Center, the discussion highlights disparities in access to colorectal cancer screening and treatments among various communities. Deneen shares her personal journey as a patient, emphasizing the importance of trust and being heard in healthcare. The episode also explores strategies to raise awareness and educate different patient groups, including leveraging trusted voices and community outreach. Tune in for valuable insights on understanding and addressing the diverse needs of patients in colorectal cancer care.
In this episode of our hematology podcast, we delve into the world of relapsed and refractory multiple myeloma with Dr. Samir A. Al-Hadidi from the University of Arkansas.
Join us as we discuss the evolving treatment options for patients who experience relapse or disease progression after initial therapy. Dr. Al-Hadidi provides valuable insights into monitoring patients, discussing escalating treatments, and the role of novel therapies such as CAR-T and bispecific antibodies.
From monitoring strategies to managing side effects, this episode of oncology podcast covers essential information for community oncologists caring for patients with relapsed or refractory multiple myeloma.
Don't miss out on this informative discussion on the current treatment landscape for multiple myeloma. Stay informed and stay connected with the latest advancements in hematology.
In this episode of the Oncology Brothers podcast, join Drs. Rahul and Rohit Gosain as they delve into the world of localized treatment options for gastrointestinal malignancies. They are joined by experts in the field, Drs. Nina Sanford, Jeffrey Ryckman, and Harris Chengazi, who provide insights into radiation oncology and interventional radiology modalities for treating liver cancer.
The discussion covers the basics of radiation oncology terminology, including SRS, SBRT, and proton therapy, and how these modalities have evolved over the last decade. The experts also discuss the various tools available in the interventional radiology toolkit, such as ablation techniques, chemoembolization, and radioembolization.
Listeners gain valuable insights into the considerations for referring patients with liver-confined hepatocellular carcinoma to radiation oncologists or interventional radiologists, depending on the size of the tumor and underlying liver function. The experts emphasize the importance of a multidisciplinary approach in cancer care to ensure the best treatment outcomes for patients.
Tune in to learn about the side effects of SBRT, the nuances of combining different treatment modalities, and the significance of collaboration among oncology specialists. This episode highlights the importance of understanding and appreciating the diverse treatment options available for cancer patients.
Don't miss out on this informative discussion on localized treatment options for gastrointestinal malignancies with the Oncology Brothers podcast.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Welcome back to another informative episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. Caitlin Costello, an associate professor specializing in multiple myeloma at UC San Diego. Together, they delve into the evolving landscape of newly diagnosed multiple myeloma, covering essential topics such as diagnostic workup, treatment paradigms, and the role of minimal residual disease (MRD) in monitoring response.
Dr. Costello provides valuable insights into the minimal workup required before initiating treatment for multiple myeloma, emphasizing the importance of advanced imaging techniques and specific biomarkers for risk assessment. The discussion also touches on tailored treatment approaches for transplant-eligible and transplant-ineligible patients, as well as maintenance therapy considerations based on risk profiles.
Throughout the episode, key points such as the use of quadruplet therapy, the significance of MRD negativity, and strategies for managing high-risk patients are explored in detail. Dr. Costello also shares practical tips for community oncologists managing multiple myeloma patients, including the importance of biomarker monitoring and prophylactic measures.
Don't miss this insightful conversation that sheds light on the latest advancements in multiple myeloma care. Stay informed and up-to-date with the Oncology Brothers podcast as they continue to provide valuable insights for oncology professionals. Subscribe now to stay connected with the latest developments in hematology oncology!
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
In this informative podcast episode, the Oncology Brothers delve into the world of hematologic malignancies, focusing specifically on Chronic Lymphocytic Leukemia (CLL). Dr. Nitin Jain from MD Anderson Cancer Center joins the discussion, sharing insights on the latest treatment options and guidelines for CLL.
The episode covers essential topics such as determining when a patient with CLL needs treatment, the minimal workup required for scans and biopsies, and the decision-making process between time-limited venetoclax and long-term BTK inhibitors. Dr. Jain also discusses the use of second-generation BTK inhibitors like Acalabrutinib and Zanabrutinib, as well as the recent approvals of Partibrutinib and CAR-T for third-line treatment.
Tune in to gain a deeper understanding of CLL treatment strategies, managing side effects, and the evolving landscape of hematologic malignancies. Don't miss out on this insightful conversation that will benefit both healthcare professionals and patients navigating CLL treatment options.
Stay informed and stay tuned for upcoming episodes on multiple myeloma and myelofibrosis with the Oncology Brothers. Subscribe now to stay updated on the latest in oncology care.
Join us for yet another episode of The Oncology Brothers podcast, where we delve into the FRESCO2 study in metastatic colorectal cancer. In this episode, we are joined by Dr. Arvind Dasari from MD Anderson, the lead author of the study, to discuss the approval of fruquintinib and its impact on refractory colorectal cancer patients.
Discover how fruquintinib has significantly improved progression-free and overall survival, providing a new treatment option for patients who have exhausted other therapies. Dr. Dasari shares insights on the study design, results, and the practical implications of incorporating fruquintinib into clinical practice.
Tune in to learn about the key findings, side effects, dosing strategies, and real-world experiences with fruquintinib in managing refractory colorectal cancer. Take advantage of this informative episode that sheds light on the evolving landscape of colon cancer treatments. Subscribe to The Oncology Brothers podcast for more insightful discussions on cancer care. #Oncology #ColorectalCancer #FRESCO2Study
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Welcome to another insightful episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. Sam Klempner, a medical oncologist specializing in upper GI malignancies. Together, they delve into the current treatment strategies for esophageal, GE junction, and gastric adenocarcinoma.
The discussion covers a range of topics, including the evolving paradigms in neoadjuvant and adjuvant therapies, the importance of biomarker testing such as MSI and PD-L1, and the potential impact of new targets like Claudin 18.2 in upper GI cancers. Dr. Klempner also shares insights on the management of metastatic disease, including the role of targeted therapies like TDXD and Zolbetuximab.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable information on the current landscape of upper GI malignancies. Stay informed and join the Oncology Brothers as they navigate the complexities of treating these challenging cancers. Don't miss out on this informative discussion!
Tune in to the Oncology Brothers podcast for more expert insights and discussions on oncology topics. Remember to like, share, and subscribe for more content on the latest developments in cancer care. Thank you for listening!
In this episode of Oncology Brothers, join hosts Drs. Rahul and Rohit as they dive into the management of colon cancer with special guest Dr. Aparna Parikh, a medical oncologist from Mass General Hospital. Dr. Parikh shares insights on the treatment algorithm for colon cancer, including the use of circulating tumor DNA and the latest advancements in treatment options. From localized disease to metastatic space, the discussion covers key aspects of managing colon cancer. Tune in to learn about the evolving landscape of colon cancer treatment and the importance of personalized patient-centered care. Don't miss out on this informative episode with the Oncology Brothers and Dr. Aparna Parikh!
Join the Oncology Brothers, Drs. Rahul and Rohit Gosain, in this engaging podcast episode as they delve into the treatment landscape for hepatocellular carcinoma (HCC) with Dr. Tanios S. Bekaii-saab from Mayo Clinic. The discussion covers the treatment options for different stages of HCC, including liver transplant, local therapy, and systemic treatments. Dr. Tanios S. Bekaii-saab provides insights on utilizing Atezolizumab with Bevacizumab, dual checkpoint inhibitors, and TKIs in advanced or metastatic HCC. Clinical pearls on managing side effects and patient selection criteria are also discussed. Don't miss this comprehensive overview of HCC treatment strategies in both community and academic settings. Stay informed and educated on the latest developments in oncology with the Oncology Brothers podcast series. Subscribe now for more insightful discussions on various cancer types and treatment approaches. #Oncology #HepatocellularCarcinoma #CancerTreatment #PodcastEpisode
Join the Oncology Brothers, Drs. Rahul and Rohit Gosain, as they dive deep into the groundbreaking EV302 study with special guest Dr. Thomas Powles. In this episode, they discuss the approval of Enfortumab and Pembrolizumab as a combination therapy for advanced bladder cancer, based on the remarkable results of the study. Dr. Powles shares insights on the study design, findings, and the transformative impact of the treatment on patients' lives. Discover how this new standard of care in bladder cancer has significantly improved overall survival benefits, with a median survival of 31.5 months compared to 16.1 months with chemotherapy. The discussion also delves into managing the side effects of the treatment and the potential use of ctDNA in monitoring disease progression. Don't miss this informative episode that sheds light on the evolving landscape of bladder cancer treatment and the hope it brings to patients. Stay tuned for a quick recap and insights from the Oncology Brothers.
Bladder Cancer Treatment Options: A Comprehensive Discussion | Oncology Brothers Podcast
Join the Oncology Brothers, Rahul Gosain and Rohit Gosain, in this insightful podcast episode where they are joined by Dr. Karine Tawagi, a medical oncologist, and Dr. Sia Daneshmand, a urologist, to discuss the current standard of care and treatment options for bladder cancer. In this episode, the experts delve into the treatment approaches for non-muscle invasive bladder cancer, including the use of BCG, pembrolizumab, and other emerging therapies. They also cover the management of muscle invasive bladder cancer, highlighting the role of neoadjuvant chemotherapy, cystectomy, and immunotherapy. The conversation extends to metastatic bladder cancer, focusing on the groundbreaking EV Pembro treatment and the evolving landscape of treatment options post-progression. The experts provide valuable insights into managing toxicities associated with different therapies and offer clinical pearls for healthcare providers. Don't miss this informative discussion on bladder cancer treatment options, featuring expert insights and practical recommendations for healthcare professionals. Tune in to the Oncology Brothers Podcast now! Listen to the full episode here. Stay informed and updated on the latest advancements in oncology with the Oncology Brothers podcast series. Subscribe now for more engaging discussions and expert insights.
#Bladder #Cancer #Treatment #Algorithm
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
In this episode joined by Dr. Monty Pal from City of Hope to discuss the latest advancements in the treatment of renal cell cancer. The conversation covers topics such as adjuvant pembrolizumab, personalized medicine, second-line treatment options, and the role of TKIs and immune checkpoint inhibitors. Dr. Pal shares insights on clinical pearls, treatment algorithms, and ongoing clinical trials in the field. Tune in to stay informed about the current standard of care practices in renal cell cancer treatment.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
In discussion with Dr. Rana McKay, Associate Professor of Medicine from UC San Diego Health, we covered the treatment algorithm for Prostate cancer, starting from localized disease and then focusing on CSPC and CRPC.
#Prostate #Cancer #Cancer #2024 #oncology #oncbrothers
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
In this discussion with Dr. Hope Rugo, we covered her study Capitello-291, which led to the approval of Capivasertib in hormone receptor-positive breast cancer with AKT1, PTEN, and PIK3CA mutations, which are seen in 40-50% of the cases. We touched base on sequencing of this therapy, and important clinical pearls around the side effect management associated with this drug.
In discussion with Dr. Virginia Kaklamani, we cover treatment algorithm of HR+ breast cancer. We covered the current standard of care treatment options for HR+ breast cancer.
#HER2 #Sensitive #Breast #Cancer #2024 #oncology #oncbrothers
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
In discussion with Dr. Tian Zhang, covering the Genitourinary ASCO 2024 meeting highlights from the Community Oncology perspective. We covered 4 important practice informing studies from GU ASCO with Dr. Zhang:
- CONTACT-02: Phase 3 study of cabozantinib plus atezolizumab vs second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer
- BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer bearing homologous recombination-repair mutations
- AMBASSADOR: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma vs observation
- Keynote-564: Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma
In discussion with Dr. Harold Burstein, we cover treatment algorithm of HER2+ breast cancer. We covered the current standard of care treatment options for HER2+ breast cancer.
#HER2 #Sensitive #Breast #Cancer #2024 #oncology #oncbrothers
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Comments
Download from Google Play
Download from App Store
United States